Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Potential drug targets for calcific aortic valve disease.

Hutcheson JD, Aikawa E, Merryman WD.

Nat Rev Cardiol. 2014 Apr;11(4):218-31. doi: 10.1038/nrcardio.2014.1. Epub 2014 Jan 21. Review.

2.

Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease.

Yutzey KE, Demer LL, Body SC, Huggins GS, Towler DA, Giachelli CM, Hofmann-Bowman MA, Mortlock DP, Rogers MB, Sadeghi MM, Aikawa E.

Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2387-93. doi: 10.1161/ATVBAHA.114.302523. Epub 2014 Sep 4. Review.

3.

Molecular and cellular aspects of calcific aortic valve disease.

Towler DA.

Circ Res. 2013 Jul 5;113(2):198-208. doi: 10.1161/CIRCRESAHA.113.300155. Review.

4.

Insights into the use of biomarkers in calcific aortic valve disease.

Beckmann E, Grau JB, Sainger R, Poggio P, Ferrari G.

J Heart Valve Dis. 2010 Jul;19(4):441-52. Review.

5.

Angiotensin receptor blockers are associated with reduced fibrosis and interleukin-6 expression in calcific aortic valve disease.

Côté N, Mahmut A, Fournier D, Boulanger MC, Couture C, Després JP, Trahan S, Bossé Y, Pagé S, Pibarot P, Mathieu P.

Pathobiology. 2014;81(1):15-24. doi: 10.1159/000350896. Epub 2013 Aug 21.

PMID:
23969418
6.

Defining the role of fluid shear stress in the expression of early signaling markers for calcific aortic valve disease.

Sun L, Rajamannan NM, Sucosky P.

PLoS One. 2013 Dec 23;8(12):e84433. doi: 10.1371/journal.pone.0084433. eCollection 2013.

7.

Progressive aortic valve calcification: three-dimensional visualization and biomechanical analysis.

Halevi R, Hamdan A, Marom G, Mega M, Raanani E, Haj-Ali R.

J Biomech. 2015 Feb 5;48(3):489-97. doi: 10.1016/j.jbiomech.2014.12.004. Epub 2014 Dec 18.

PMID:
25553668
8.

The effect of oxLDL on aortic valve calcification via the Wnt/ β-catenin signaling pathway: an important molecular mechanism.

Gao X, Zhang L, Gu G, Wu PH, Jin S, Hu W, Zhan C, Li J, Li Y.

J Heart Valve Dis. 2015 Mar;24(2):190-6.

PMID:
26204684
9.

The progression of calcific aortic valve disease through injury, cell dysfunction, and disruptive biologic and physical force feedback loops.

Li C, Xu S, Gotlieb AI.

Cardiovasc Pathol. 2013 Jan-Feb;22(1):1-8. doi: 10.1016/j.carpath.2012.06.005. Epub 2012 Jul 12. Review.

PMID:
22795219
10.

The role of TNF-α and TNF superfamily members in the pathogenesis of calcific aortic valvular disease.

Galeone A, Paparella D, Colucci S, Grano M, Brunetti G.

ScientificWorldJournal. 2013 Nov 6;2013:875363. doi: 10.1155/2013/875363.

11.

Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization.

Mahmut A, Boulanger MC, El Husseini D, Fournier D, Bouchareb R, Després JP, Pibarot P, Bossé Y, Mathieu P.

J Am Coll Cardiol. 2014 Feb 11;63(5):460-9. doi: 10.1016/j.jacc.2013.05.105. Epub 2013 Oct 23.

12.

Multimodality and molecular imaging of matrix metalloproteinase activation in calcific aortic valve disease.

Jung JJ, Razavian M, Challa AA, Nie L, Golestani R, Zhang J, Ye Y, Russell KS, Robinson SP, Heistad DD, Sadeghi MM.

J Nucl Med. 2015 Jun;56(6):933-8. doi: 10.2967/jnumed.114.152355. Epub 2015 Apr 23.

PMID:
25908827
13.

Basic mechanisms of calcific aortic valve disease.

Mathieu P, Boulanger MC.

Can J Cardiol. 2014 Sep;30(9):982-93. doi: 10.1016/j.cjca.2014.03.029. Epub 2014 Mar 27. Review.

PMID:
25085215
14.

Computational assessment of bicuspid aortic valve wall-shear stress: implications for calcific aortic valve disease.

Chandra S, Rajamannan NM, Sucosky P.

Biomech Model Mechanobiol. 2012 Sep;11(7):1085-96.

PMID:
22294208
15.

[Calcified aortic valve disease: association with atherosclerosis].

Toro R, Mangas A, Gómez F.

Med Clin (Barc). 2011 May 14;136(13):588-93. doi: 10.1016/j.medcli.2010.02.019. Epub 2010 Apr 24. Review. Spanish.

PMID:
20417530
16.

Ex vivo evidence for the contribution of hemodynamic shear stress abnormalities to the early pathogenesis of calcific bicuspid aortic valve disease.

Sun L, Chandra S, Sucosky P.

PLoS One. 2012;7(10):e48843. doi: 10.1371/journal.pone.0048843. Epub 2012 Oct 31.

17.

Aortic valvular heart disease: Is there a place for angiotensin-converting-enzyme inhibitors?

Elder DH, McAlpine-Scott V, Choy AM, Struthers AD, Lang CC.

Expert Rev Cardiovasc Ther. 2013 Jan;11(1):107-14. doi: 10.1586/erc.12.143. Review.

PMID:
23259450
18.

Analysis of osteopontin levels for the identification of asymptomatic patients with calcific aortic valve disease.

Grau JB, Poggio P, Sainger R, Vernick WJ, Seefried WF, Branchetti E, Field BC, Bavaria JE, Acker MA, Ferrari G.

Ann Thorac Surg. 2012 Jan;93(1):79-86. doi: 10.1016/j.athoracsur.2011.08.036. Epub 2011 Nov 16.

19.

Mechanisms of calcification in aortic valve disease: role of mechanokinetics and mechanodynamics.

Merryman WD, Schoen FJ.

Curr Cardiol Rep. 2013 May;15(5):355. doi: 10.1007/s11886-013-0355-5. Review.

20.

[Congenital heart disease and acquired valvular lesions in pregnancy].

Horstkotte D, Fassbender D, Piper C.

Herz. 2003 May;28(3):227-39. Review. German.

PMID:
12756480
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk